FrancophonIA/ELRC3.0 huggingface dataset:
English: Following the introduction of Prevenar and subsequently Prevenar 13 there was a decline in incidence from 2.1 to 0.1 cases per 1000 children (95%) for the Prevenar serotypes plus serotype 6A and a decline in incidence from 0.9 to 0.1 cases per 1000 children (89%) for the additional serotypes 1, 3, 5, 7F, and 19A in Prevenar 13.
Croatian: Nakon uvođenja Prevenara i potom Prevenara 13 došlo je do smanjenja pojavnosti od 2,1 do 0,1 slučajeva na 1000 ispitivane djece (95%) za serotipove Prevenara i serotip 6A te smanjenja pojavnosti od 0,9 do 0,1 slučajeva na 1000 djece (89%) za dodatne serotipove 1, 3, 5, 7F i 19A u Prevenaru 13. Godišnja učestalost pneumokokne incidencije upale srednjeg uha smanjila se s 9,6 na 2,1 slučaja na 1000 djece (78%) između srpnja 2004. god. (prije uvođenja Prevenara) i lipnja 2013. god. (nakon uvođenja Prevenara 13).
English: For the 7 common serotypes there were no differences between groups in the proportion of subjects with OPA titres ≥ 1:8.
Croatian: Nije bilo razlike između skupina u udjelu ispitanika s OPA titrom ≥ 1:8 za 7 čestih serotipova.
English: Prevenar 13 elicited comparable, although slightly lower, antibody levels than Prevenar for the 7 common serotypes.
Croatian: Prevenar 13 izazvao je usporedive razine protutijela protiv 7 čestih serotipova, premda nešto niže nego Prevenar.
English: Prevenar 13 suspension for injection in multidose container IM
Croatian: Prevenar 13 suspenzija za injekciju u višedoznom spremniku i.m.
English: Pneumococcal polysaccharide serotype 9V
Croatian: Pneumokokni polisaharid serotipa 9V
English: 0.5 ml suspension for injection in a vial (Type I glass) with a latex-free grey chlorobutyl rubber stopper and sealed with an aluminum flip-off seal and a polypropylene flip-off cap.
Croatian: 0,5 ml suspenzije za injekcije u bočici (staklo tipa I) sa sivim čepom od klorobutilne gume koja ne sadrži lateks, zabrtvljena aluminijskim „flip-off” prstenom i polipropilenskim „flip-off” zatvaračem.
English: Adults with a blood-forming stem cell transplant had similar side effects however the frequencies were very common for fever and vomiting.
Croatian: Odrasle osobe s presađenim krvotvornim matičnim stanicama imale su slične nuspojave, međutim učestalosti za vrućicu i povraćanje bile su vrlo često.
English: Table 7 compares the OPA GMTs, 1-month post-dose, in 60-64 year olds given either a single dose of Prevenar 13 or 23-valent pneumococcal polysaccharide vaccine, and in 50-59 year olds given a single dose of Prevenar 13.
Croatian: Tablica 7 uspoređuje geometrijske sredine OPA titara, 1 mjesec nakon primjene doze, u osoba u dobi od 60 do 64 godine koje su primile jednu dozu Prevenara 13 ili 23-valentnog pneumokoknog polisaharidnog cjepiva i u osoba u dobi od 50 do 59 godina koje su dobile jednu dozu Prevenara 13.
English: • Each injection will be given at least one month apart.
Croatian: • Injekcije će se davati u razmaku od najmanje mjesec dana.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'.
Croatian: Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po dozi, odnosno zanemarive količine natrija.
English: (2006) 2, 4, + 13 months
Croatian: 2, 4, + 13 mjeseci
English: Infants and children who have previously received Prevenar may receive Prevenar 13 to complete the course of injections.
Croatian: Dojenčad i djeca koja su prethodno cijepljena Prevenarom mogu dovršiti seriju cijepljenja i Prevenarom 13.
English: Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.
Croatian: Aktivna imunizacija dojenčadi, djece i adolescenata u dobi od 6 tjedana do 17 godina radi prevencije invazivne bolesti, upale pluća i akutne upale srednjeg uha prouzročenih bakterijom Streptococcus pneumoniae.
English: The vaccine is a white suspension for injection, provided in a single-dose vial (0.5 ml).
Croatian: Cjepivo je bijela suspenzija za injekciju, u jednodoznoj napunjenoj štrcaljki (0,5 ml).
English: In adults aged 60-64 years, OPA GMTs to Prevenar 13 were non-inferior to the OPA GMTs elicited to the 23-valent pneumococcal polysaccharide vaccine for the twelve serotypes common to both vaccines.
Croatian: U odraslih u dobi od 60 do 64 godine, geometrijske sredine OPA titra na Prevenar 13 bile su neinferiorne geometrijskoj sredini OPA titra izazvanog 23-valentnim pneumokoknim polisaharidnim cjepivom za dvanaest serotipova prisutnih u oba cjepiva.
English: OPA GMT levels at baseline OPA GMT levels one year after Prevenar 13
Croatian: Početne razine OPA GMT Razine OPA GMT godinu dana nakon Prevenara 13
English: Immune responses after the fourth dose of Prevenar 13 were significantly increased for all serotypes compared with after the third dose.
Croatian: Prevenar 13 potaknuo je povišene razine protutijela nakon svake doze Prevenara 13. Imunološki odgovori nakon četvrte doze Prevenara 13 bili su značajno viši za sve serotipove u usporedbi s odgovorima nakon treće doze.
English: Table 9 compares the OPA GMTs, 1-month post-dose, in pneumococcal polysaccharide vaccinated adults aged ≥ 70 years given a single dose of either Prevenar 13 or 23-valent pneumococcal polysaccharide vaccine.
Croatian: Tablica 9 uspoređuje geometrijske sredine OPA titara (OPA GMT, 1 mjesec nakon doze, u odraslih osoba cijepljenih pneumokoknim polisaharidnim cjepivom u dobi ≥ 70 godina koje su dobile jednu dozu ili Prevenara 13 ili 23-valentnog pneumokoknog polisaharidnog cjepiva.
English: % Incidence reduction (95% CI*)
Croatian: % smanjenje pojavnosti (95% CI*)
English: Children < 5
Croatian: Djeca < 5 godina
English: Adults with an haematopoietic stem cell transplant have similar frequencies of adverse reactions, except that pyrexia and vomiting were very common.
Croatian: Odrasle osobe s presađenim hematopoetskim matičnim stanicama imale su sličnu učestalost nuspojava osim što su pireksija i povraćanje bili vrlo česti.
English: • Hives (urticaria or urticaria-like rash)
Croatian: • koprivnjača (urtikarija ili osip sličan urtikariji)
English: Pneumococcal polysaccharide serotype 19A
Croatian: Pneumokokni polisaharid serotipa 19A
English: The recommended immunisation series consists of four doses, each of 0.5 ml.
Croatian: Preporučuje se imunizacija serijom od četiri doze, svaka po 0,5 ml.
English: General disorders and administration site conditions: Vaccination-site urticaria; vaccination-site dermatitis; vaccination-site pruritus; flushing
Croatian: Opći poremećaji i reakcije na mjestu primjene: urtikarija na mjestu primjene cjepiva; dermatitis na mjestu primjene cjepiva; svrbež na mjestu primjene cjepiva; naleti crvenila
English: The primary infant series consists of three doses, with the first dose given at 2 months of age and with an interval of at least 1 month between doses.
Croatian: Primarna serija imunizacije dojenčadi sastoji se od tri doze, s prvom dozom koja se daje u 2. mjesecu života te s intervalom od najmanje mjesec dana između doza.
English: One year after vaccination with Prevenar 13 in adults aged 70 years and over who were vaccinated with 23-valent pneumococcal polysaccharide vaccine, at least 5 years prior to study entry, OPA titers had declined compared to one month after vaccination, however, OPA titers for all serotypes remained higher than levels at baseline:
Croatian: Godinu dana nakon cijepljenja Prevenarom 13 u odraslih osoba u dobi od 70 ili više godina koje su prethodno bile cijepljene 23-valentnim pneumokoknim polisaharidnim cjepivom najmanje 5 godina prije uključenja u ispitivanje, OPA titri opali su u usporedbi s vrijednostima mjesec dana nakon cijepljenja.
English: What Prevenar 13 contains
Croatian: Što Prevenar 13 sadrži
English: It is recommended that infants who receive a first dose of Prevenar 13 complete the vaccination course with Prevenar 13.
Croatian: U dojenčadi koja je primila prvu dozu Prevenara 13 preporučuje se cijepljenje dovršiti Prevenarom 13.
English: Serotype
Croatian: Serotip
English: For children 1 to 5 years of age previously vaccinated with Prevenar, your doctor or nurse will recommend how many injections of Prevenar 13 are required.
Croatian: Vaš liječnik ili medicinska sestra preporučit će koliko je injekcija Prevenara 13 potrebno u djece u dobi od 1 do 5 godina prethodno cijepljene Prevenarom.
English: Immune responses following a two-dose primary infant series
Croatian: Imunološki odgovor nakon primarne serije cijepljenja s 2 doze u dojenčadi
English: Skin and subcutaneous tissue disorders: Very common:
Croatian: Poremećaji kože i potkožnog tkiva: Vrlo često:
English: Incidence reduction (95% CI*)
Croatian: smanjenje pojavnosti (95% CI*)
English: Haematopoietic stem cell transplant
Croatian: Presađene hematopoetske matične stanice
English: Chills; fatigue; vaccination-site erythema; vaccination-site induration/swelling; vaccination-site pain/tenderness (severe vaccination-site pain/tenderness very common in adults aged 18 to 39 years); limitation of arm movement (severe limitation of arm movements very common in adults aged 18 to 39 years)
Croatian: zimica; umor; eritem na mjestu primjene injekcije; otvrdnuće/oteklina na mjestu primjene injekcije (jaka bol/osjetljivost na mjestu primjene injekcije vrlo često u odraslih u dobi od 18 do 39 godina); ograničena pokretljivost ruke (jako ograničena pokretljivost ruke vrlo često u odraslih u dobi od 18 do 39 godina)
English: Prevenar 13 must not be administered intravascularly.
Croatian: Prevenar 13 ne smije se primijeniti intravenski.
English: Effectiveness of Prevenar in a 3+1 schedule has also been observed against acute otitis media and pneumonia since its introduction in a national immunisation programme.
Croatian: Nakon uvođenja Prevenara u nacionalni program cijepljenja, promatrana je njegova učinkovitost i protiv akutne upale srednjeg uha i upale pluća kad se davao prema rasporedu 3+1.
English: The clinical relevance of these differences is not known.
Croatian: Klinička važnost ovih nalaza nije poznata.
English: Immune responses following a three-dose primary infant series
Croatian: Imunološki odgovori nakon primarne serije cijepljenja od tri doze u dojenčadi
English: Musculoskeletal and connective tissue disorders: Very common:
Croatian: Poremećaji mišićno-koštanog sustava i vezivnog tkiva: Vrlo često:
English: The first dose was administered at 3 to 6 months after HSCT.
Croatian: Prva je doza primijenjena tri do šest mjeseci nakon presađivanja hematopoetskih matičnih stanica.
English: Pneumococcal polysaccharide serotype 23F
Croatian: Pneumokokni polisaharid serotipa 23F
English: Adults 50-59 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Croatian: Odrasle osobe u dobi od 50 do 59 godina koje prethodno nisu bile cijepljene 23-valentnim pneumokoknim polisaharidnim cjepivom
English: In adults aged 18-49 years, OPA GMTs to all 13 serotypes in Prevenar 13 were non-inferior to the Prevenar 13 responses in adults aged 60-64 years.
Croatian: U odraslih osoba u dobi od 18 do 49 godina, geometrijske sredine OPA titara na svih 13 serotipova u Prevenaru 13 bile su neinferiorne odgovoru na Prevenar 13 u odraslih osoba u dobi od 60 do 64 godine.
English: In adults aged 50-59 years, OPA GMTs to all 13 serotypes in Prevenar 13 were non-inferior to the Prevenar 13 responses in adults aged 60-64 years.
Croatian: U odraslih osoba u dobi od 50 do 59 godina, geometrijske sredine OPA titara na svih 13 serotipova u Prevenaru 13 bile su neinferiorne odgovoru na Prevenar 13 u odraslih osoba u dobi od 60 do 64 godine.
English: Table 9: OPA GMTs in pneumococcal polysaccharide vaccinated adults aged ≥ 70 years given either Prevenar 13 or 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Croatian: ≥ 70 godina cijepljenih pneumokoknim polisaharidnim cjepivom koje su dobile Prevenar 13 ili 23-valentno pneumokokno polisaharidno cjepivo (PPSV23)
English: EU/1/09/590/002 - pack of 1 with separate needle EU/1/09/590/001 - pack of 1 without needle EU/1/09/590/004 - pack of 10 with separate needles EU/1/09/590/003 - pack of 10 without needle EU/1/09/590/006 - pack of 50 with separate needles EU/1/09/590/005 - pack of 50 without needle
Croatian: EU/1/09/590/002 - pakiranje od 1 sa zasebno priloženom iglom EU/1/09/590/001 - pakiranje od 1 bez igle EU/1/09/590/004 - pakiranje od 10 sa zasebno priloženim iglama EU/1/09/590/003 - pakiranje od 10 bez igle EU/1/09/590/006 - pakiranje od 50 sa zasebno priloženim iglama EU/1/09/590/005 - pakiranje od 50 bez igle
English: Pneumococcal polysaccharide serotype 19F
Croatian: Pneumokokni polisaharid serotipa 19F
English: Pneumococcal polysaccharide serotype 6B
Croatian: Pneumokokni polisaharid serotipa 6B
English: Adults ≥ 18 years and elderly
Croatian: ≥ 18 godina i starije osobe
English: The functional antibody (OPA) geometric mean titres for serotypes 1, 3 and 5 were lower than the titres for each of the other additional serotypes; the clinical relevance of this observation for protective efficacy is unknown.
Croatian: Geometrijska sredina vrijednosti titra funkcionalnih protutijela (OPA) protiv serotipova 1, 3 i 5 bio je niži od titra protutijela protiv svakog od preostalih dodatnih serotipova; nije poznata klinička važnost ovog nalaza u pogledu djelotvornosti zaštite.
English: • Rash; hives (urticaria or urticaria-like rash)
Croatian: • osip; koprivnjača (urtikarija ili osip sličan urtikariji)
English: After the second and third dose of Prevenar 13, immune responses were similar or higher than those after the first dose.
Croatian: Imunološki su odgovori nakon druge i treće doze Prevenara 13 bili slični onima nakon prve doze ili viši od njih.
English: Pneumococcal polysaccharide serotype 7F
Croatian: Pneumokokni polisaharid serotipa 7F
English: Adults with HIV infection have similar frequencies of adverse reactions, except that pyrexia and vomiting were very common and nausea common.
Croatian: Odrasli bolesnici s HIV-om imali su sličnu učestalost nuspojava osim što su pireksija i povraćanje bili vrlo česti i mučnina česta.
English: If your child should become unresponsive or experience seizures (fits) after the vaccination, please contact your doctor immediately.
Croatian: • ako ste imali napadaje jer će u tom slučaju možda biti potrebno primijeniti lijekove za snižavanje vrućice prije primjene Prevenara 13. Ako Vaše dijete prestane reagirati ili ima napadaje nakon cijepljenja, molimo odmah kontaktirajte Vašeg liječnika.
English: How to store Prevenar 13
Croatian: Kako čuvati Prevenar 13
English: • Fever; irritability; pain, tenderness, redness, swelling or hardness at the vaccination-site;
Croatian: • razdražljivost; ; bol, osjetljivost, crvenilo, oticanje ili otvrdnuće na mjestu primjene cjepiva;
English: Pneumococcal polysaccharide serotype 6A
Croatian: Pneumokokni polisaharid serotipa 6A
English: Total
Croatian: Ukupn
English: Headaches
Croatian: glavobolje
English: Adults 60-64 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Croatian: Odrasle osobe u dobi od 60 do 64 godina koje prethodno nisu bile cijepljene 23-valentnim pneumokoknim polisaharidnim cjepivom
English: In preterm infants, the recommended immunisation series consists of four doses, each of 0.5 ml.
Croatian: Preporučena serija imunizacije u prijevremeno rođene dojenčadi se sastoji od četiri doze, a svaka doza sadrži 0,5 ml.
English: Prevenar 13.
Croatian: Nemojte primjenjivati Prevenar 13
English: METHOD AND ROUTE(S) OF ADMINISTRATION
Croatian: NAČIN I PUT(OVI) PRIMJENE LIJEKA
English: Adults previously vaccinated with 23-valent pneumococcal polysaccharide vaccine HIV-infected adults ≥ 18 years of age with CD4 ≥ 200 cells/µL (mean 609.1 cells/µL) and viral load < 50,000 copies/ml (mean 330.6 copies/ml), who were free of active AIDS-related illness and were previously vaccinated with 23-valent pneumococcal polysaccharide vaccine administered at least 6 months prior to enrollment, received 3 doses of Prevenar 13, at enrollment, 6 months, and 12 months after the first dose of Prevenar 13.
Croatian: ≥ 18 godina u kojih su opažene vrijednosti CD4 ≥200 stanica/µl (srednja vrijednost 609,1 stanica/µl) i virusno opterećenje < 50 000 kopija/ml (srednja vrijednost 330,6 kopija/ml) te bez bolesti povezanih s aktivnom SIDA-om koji su prethodno cijepljeni s 23valentnim polisaharidnim cjepivom protiv pneumokoka koje se primjenjivalo najmanje 6 mjeseci prije uključenja u ispitivanje.
English: Adults not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Croatian: Odrasle osobe koje prethodno nisu bile cijepljene 23-valentnim pneumokoknim polisaharidnim cjepivom
English: An open label single arm study in France, Italy, UK, US, Lebanon, Egypt and Saudi Arabia with 2 doses of Prevenar 13 given 6 months apart was conducted in 158 children and adolescents ≥ 6 to
Croatian: Otvoreno ispitivanje jedne skupine s 2 doze cjepiva Prevenar 13 koje se davalo u razmaku od 6 mjeseci provedeno je u Francuskoj, Italiji, Ujedinjenom Kraljevstvu, SAD-u, Libanonu, Egiptu i Saudijskoj Arabiji na 158 djece i adolescenata u dobi ≥6 do <18 godina s bolesti srpastih stanica koja su prethodno cijepljeni s jednom ili više doza 23-valentnog polisaharidnog cjepiva protiv pneumokoka najmanje 6 mjeseci prije uključivanja.
English: The other ingredients are sodium chloride, succinic acid, polysorbate 80, 2- phenoxyethanol and water for injections.
Croatian: Drugi sastojci su natrijev klorid, sukcinatna kiselina, polisorbat 80, 2-fenoksietanol i voda za injekcije.
English: The most common side effects (these may occur with more than 1 in 10 doses of the vaccine) are:
Croatian: Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 doza cjepiva) su:
English: Incidence rate reduction (95% CI)
Croatian: Smanjenje stope incidencije (95% CI)
English: Rare side effects (these may occur with up to 1 in 1,000 doses of the vaccine) are:
Croatian: Rijetke nuspojave (mogu se pojaviti u manje od 1 na 1000 doza cjepiva) su:
English: • Irritability; pain, tenderness, redness, swelling or hardness at the vaccination-site; drowsiness;
Croatian: • razdražljivost; bol, osjetljivost, crvenilo, oticanje ili otvrdnuće na mjestu primjene cjepiva;
English: The other ingredients are sodium chloride, succinic acid, polysorbate 80 and water for injections.
Croatian: Drugi sastojci su natrijev klorid, sukcinatna kiselina, polisorbat 80 i voda za injekcije.
English: The following frequencies are based on adverse reactions assessed in Prevenar 13 clinical studies:
Croatian: Sljedeće učestalosti temelje se na nuspojavama za koje se u kliničkim ispitivanjima procijenilo da su povezane s Prevenarom 13:
English: Sodium chloride, succinic acid, polysorbate 80 and water for injections
Croatian: Natrijev klorid, sukcinatna kiselina, polisorbat 80 i voda za injekcije
English: Sodium chloride, succinic acid, polysorbate 80, 2-phenoxyethanol and water for injections
Croatian: Natrijev klorid, sukcinatna kiselina, polisorbat 80, 2-fenoksietanol i voda za injekcije
English: However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.
Croatian: Međutim, cijepljenje nije potrebno odgoditi ako je prisutna lakša infekcija, kao što je prehlada.
English: Adults ≥ 18 years of age, and the elderly
Croatian: Odrasli u dobi od ≥ 18 godina i starije osobe
English: The responses to all three TIV antigens were comparable when TIV was given alone or concomitantly with Prevenar 13.
Croatian: Odgovori na sva tri antigena u trovalentnom inaktiviranom cjepivu protiv gripe bili su usporedivi kad se to cjepivo davalo samo i kad se davalo istodobno s Prevenarom 13.
English: EU/1/09/590/012 - pack of 1 multidose container EU/1/09/590/013- pack of 5 multidose containers EU/1/09/590/014- pack of 10 multidose containers EU/1/09/590/015 - pack of 25 multidose containers EU/1/09/590/016- pack of 50 multidose containers
Croatian: EU/1/09/590/012 - pakiranje s 1 višedoznim spremnikom EU/1/09/590/013 - pakiranje s 5 višedoznih spremnika EU/1/09/590/014 - pakiranje s 10 višedoznih spremnika EU/1/09/590/015 - pakiranje s 25 višedoznih spremnika EU/1/09/590/016 - pakiranje s 50 višedoznih spremnika
English: Secondary endpoints First episode of confirmed NB/NI vaccine type pneumococcal CAP
Croatian: Prva epizoda potvrđenog NB/NI CAP-a uzrokovanog pneumokokom vrste koja je prisutna u cjepivu
English: Children and adolescents 5-17 years
Croatian: Djeca i adolescenti od 5-17 godina
English: Pack sizes of 1, 5, 10, 25 and 50 vials.
Croatian: Veličine pakiranja od 1, 5, 10, 25 i 50 spremnika.
English: Adults 18-49 years not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Croatian: Odrasle osobe u dobi od 18 do 49 godina koje prethodno nisu bile cijepljene 23-valentnim pneumokoknim polisaharidnim cjepivom
English: January 2005 to December 2007.
Croatian: (2004. nasuprot 1997-99. godini).
English: Sickle cell disease
Croatian: Bolest srpastih stanica
English: Relative to 60-64 Years
Croatian: 18-49-godišnjaci u odnosu na 60-64-godišnjake
English: EU/1/09/590/007 - pack of 1 vial EU/1/09/590/008 - pack of 5 vials EU/1/09/590/009 - pack of 10 vials EU/1/09/590/010 - pack of 25 vials EU/1/09/590/011 - pack of 50 vials
Croatian: EU/1/09/590/007 - pakiranje s 1 bočicom EU/1/09/590/008 - pakiranje s 5 bočica EU/1/09/590/009 - pakiranje s 10 bočica EU/1/09/590/010 - pakiranje s 25 bočica EU/1/09/590/011 - pakiranje s 50 bočica
English: Nausea
Croatian: mučnina
English: Please speak to your doctor, pharmacist, or nurse for more information.
Croatian: Za dodatne informacije obratite se svom liječniku, ljekarniku ili medicinskoj sestri.
English: Recommended schedule
Croatian: Preporučeni raspored cijepljenja
English: Pneumococcal polysaccharide serotype 1
Croatian: Pneumokokni polisaharid serotipa 1
English: In a published study performed in Israel, using a 2-dose primary series plus booster dose in the second year of life, the impact of Prevenar 13 on OM was documented in a population-based
Croatian: U objavljenom ispitivanju koje je provedeno u Izraelu primjenjujući primarne serije od 2- doze uz docjepljivanje jednom dozom u drugoj godini života, učinak Prevenara 13 na upalu srednjeg uha dokumentiran je u populaciji na temelju sustava promatranja na kultiviranju timpanocenteze iz tekućine srednjeg uha u izraelske djece mlađe od 2 godine starosti sa upalom srednjeg uha.
English: Pneumococcal polysaccharide serotype 14
Croatian: Pneumokokni polisaharid serotipa 14
English: Pneumococcal polysaccharide serotype 5
Croatian: Pneumokokni polisaharid serotipa 5
English: • Decreased appetite; headaches; diarrhoea; vomiting (for those 18 to 49 years of age) • Chills; tiredness; rash; pain, redness, swelling hardness or tenderness at the vaccination-site,
Croatian: • smanjeni apetit; glavobolje; proljev; povraćanje (u dobi od 18 do 49 godina)
English: Tηλ: +357 22 817690
Croatian: Pfizer Ελλάς Α.Ε. (Cyprus Branch) Tηλ: +357 22 817690
English: 7-valent Prevenar serotypes
Croatian: Serotipovi u 7-valentnom Prevenaru
English: Prevenar 13 suspension for injection in single dose vial IM
Croatian: Prevenar 13 suspenzija za injekciju u jednodoznoj bočici i.m.
English: Children and adolescents aged 6 to 17 years
Croatian: Djeca i adolescenti od 6 do 17 godina
English: Children and Adolescents 5 to 17 years of age
Croatian: Djeca i adolescenti od 5 do 17 godina
English: Excipients with known effect For the full list of excipients, see section 6.1.
Croatian: Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
English: Adults previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Croatian: Odrasli koji su prethodno cijepljeni 23-valentnim polisaharidnim cjepivom protiv pneumokoka HIV-om zaraženi odrasli u dobi
English: Children and adolescents aged 6 to 17 years of age
Croatian: Djeca i adolescenti u dobi od 6 do 17 godina